

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), April 25, 2019

RELEVANT FACT

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), informs that the Ordinary and Extraordinary General Shareholders' Meeting was held upon the first call on April 25, 2019, with the agenda established and present shareholders owning 73,75 % of the share capital.

All resolutions were adopted by the legal and statutory majorities, being the following:

1. The individual and consolidated financial statements and the individual and consolidated management reports, the allocation of result obtained by the individual company during the year (€ 9,033,815.00) to the provision of voluntary reserves and the conduct of business of the board of directors, all of that regarding the year 2018.
2. The re-appointment of members of the company's Board of Directors.
3. The re-election of "KPMG Auditores, SL" as the auditors of the Company and its consolidated Group for a period of one year.
4. The Annual Report on the Remuneration of the Directors of the Company corresponding to 2018, with a consultative vote.
5. The new long-term loyalty plan for Executives of the Company.



6. Within "Reig Jofre Flexible Dividend" plan, an increase in the Company's share capital with a charge to reserves for an amount determined in accordance with the terms of the agreement, through the issuance of new ordinary shares with a nominal value of fifty cents and with provision for incomplete allocation. Offer to shareholders for the purchase of their free allocation rights for a guaranteed price. Request for admission to trading of issued shares. Delegation of powers to the Board of Directors, with express power of substitution, for the specification of the details concerning said capital increase. The sum of the reference market value of the New Shares, in accordance with the agreement, will have a maximum limit of € 3,000,000.
7. The authorization of the Board of Directors, with express powers of substitution, to carry out the derivative acquisition of treasury stock, either directly or via subsidiaries, with the limits and requirements established in the Corporate Enterprises Act, thus superseding the authorization granted in the General Shareholders Meeting of June 26, 2016.
8. For the call of extraordinary shareholders' meetings, up to the celebration of the next Ordinary General Shareholders Meeting, the applicable term be fifteen days.
9. The board of directors, with express power of substitution, were granted powers for the formalization, interpretation, correction and/or implementation of the agreements adopted by the General Shareholders Meeting.

Yours faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA